Although the rational combination of Akt pathway inhibition with perifosine and proteasome inhibition with bortezomib demonstrated synergistic anti‐MM activity in preclinical investigation [19], this was not reflected in the phase 3 clinical setting, despite earlier‐phase clinical studies showing promise. Here, AKT1 is linked to Miyoshi myopathy.